Analytical Data
-
Gene name
BMP-13/GDF-6
- Application
-
Alternative Names
BMP13; CDMP2; GDF16; Bone morphogenetic protein 13; Growth/differentiation factor 16
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
Q6KF10
-
Expression Region
Thr336~Arg455
-
Protein Length
Partial
-
Molecular Weight
16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BMP-13 (Bone Morphogenetic Protein-13), also known as GDF-6 (Growth and Differentiation Factor-6), is a member of the transforming growth factor-beta (TGF-β) superfamily. It plays a crucial role in various biological processes, including embryonic development, bone formation, and tissue regeneration. The significance of BMP-13/GDF-6 in developmental biology has garnered attention due to its potential applications in regenerative medicine and orthopedic therapies. Research has indicated that BMP-13 promotes the differentiation of mesenchymal stem cells into chondrocytes and osteoblasts, thereby facilitating cartilage and bone tissue engineering. Furthermore, its regulatory effects on cellular signaling pathways make it a vital player in the maintenance of bone homeostasis and repair mechanisms. Due to these critical functions, recombinant BMP-13/GDF-6 proteins have been extensively studied for their therapeutic potential in treating conditions like osteoarthritis, osteoporosis, and fractures. Understanding the molecular mechanisms underlying the activity of BMP-13/GDF-6 is essential for developing innovative treatments that harness its regenerative properties. Recent advancements in recombinant protein technologies have enabled the production of bioactive BMP-13/GDF-6, paving the way for preclinical and clinical investigations. As a result, the exploration of BMP-13/GDF-6 in experimental models and clinical settings continues to expand, offering promising insights into enhancing musculoskeletal health and improving outcomes for patients with skeletal disorders.
